[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100640562":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":29,"centralContacts":34,"locations":39,"responsibleParty":66,"collaborators":25,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":25,"eligibilityCriteria":74,"healthyVolunteers":70,"sex":75,"minAge":76,"maxAge":25,"enrollmentInfo":77,"targetDuration":25,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":87,"overallStatus":102,"whyStopped":25,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":112},{"fullName":5,"class":6},"Baylor Research Institute","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Epic Clinician Notification","EXPERIMENTAL","Treating clinicians receive an Epic in-basket notification identifying confirmed albuminuria and potential eligibility for guideline-directed CKM therapies using existing EHR data. All treatment decisions remain at the discretion of the treating clinician.",[13],"Other: Epic-Based Clinician Notification",{"label":15,"type":16,"description":17,"interventionNames":18},"Usual Care","ACTIVE_COMPARATOR","Participants receive standard clinical care without Epic clinician notification. Treatment decisions, including initiation of guideline-directed CKM therapies, remain at the discretion of the treating clinician.",[19],"Other: Usual Care",[21,26],{"type":6,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"Epic-Based Clinician Notification","Epic in-basket clinician notification identifying confirmed albuminuria and potential eligibility for guideline-directed CKM therapies using existing EHR data.",[9],null,{"type":6,"name":15,"description":27,"armGroupLabels":28,"otherNames":25},"Standard clinical care without Epic clinician notification.",[15],[30],{"name":31,"affiliation":32,"role":33},"Shahzeb Khan, MD","Baylor Scott and White Health","PRINCIPAL_INVESTIGATOR",[35],{"name":31,"role":36,"phone":37,"phoneExt":25,"email":38},"CONTACT","469-326-2636","shahzeb.khan@bswhealth.org",[40,54],{"facility":32,"status":25,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Dallas","Texas","75246","United States","US",{"type":47,"coordinates":48},"Point",[49,50],-96.80667,32.78306,{"lat":50,"lon":49},[53],{"name":31,"role":36,"phone":37,"phoneExt":25,"email":38},{"facility":55,"status":25,"city":56,"state":42,"zip":57,"country":44,"countryCode":45,"cosmosGeoPoint":58,"geoPoint":62,"contacts":63},"Baylor Scott and White, Advanced Heart Care","Plano","75093",{"type":47,"coordinates":59},[60,61],-96.69889,33.01984,{"lat":61,"lon":60},[64,65],{"name":31,"role":36,"phone":37,"phoneExt":25,"email":38},{"name":31,"role":33,"phone":25,"phoneExt":25,"email":25},{"type":67,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100640562","randomized-ehr-based-prescribing-to-improve-disease-modifying-therapies-for-cardio-kidney-metabolic-care-rapid-ckm-100640562",false,"NCT07605390","RAndomized EHR-based Prescribing to Improve Disease-modifying Therapies for Cardio-Kidney-Metabolic Care (RAPID-CKM)","RAPID-CKM: RAndomized EHR-based Prescribing to Improve Disease-modifying Therapies for Cardio-Kidney-Metabolic Care.","Inclusion Criteria\n\n* Adults aged ≥18 years\n* Diagnosis of type 2 diabetes mellitus\n* Receiving outpatient care within Baylor Scott \\& White Health\n* At least 1 outpatient encounter within the preceding 12 months\n* Confirmed albuminuria (UACR \\>30 mg\u002Fg)\n* Eligible for one or more guideline-directed CKM therapies based on - prespecified clinical criteria and EHR review\n\nExclusion Criteria:\n\n* Type 1 diabetes mellitus\n* Contraindication or documented intolerance to all eligible guideline-directed CKM therapies\n* Advanced kidney dysfunction below recommended initiation thresholds for SGLT2i or finerenone\n* Hyperkalemia or elevated baseline serum potassium precluding safe therapy initiation\n* Contraindicated drug interactions (e.g., strong CYP3A inhibitors with finerenone)\n* Other guideline- or labeling-based contraindications to therapy initiation","ALL","18 Years",{"count":78,"type":79},600,"ESTIMATED","INTERVENTIONAL",[82],"NA","The goal of this pragmatic randomized clinical trial is to determine whether an Epic-based clinician notification increases initiation of guideline-directed cardio-kidney-metabolic (CKM) therapies in adults with type 2 diabetes and confirmed albuminuria.\n\nThe main question it aims to answer is:\n\n• Does an Epic clinician notification improve initiation of guideline-directed CKM therapies compared with usual care?\n\nResearchers will compare an Epic in-basket clinician notification strategy with usual care.\n\nIn the intervention arm, the treating clinician will receive an Epic notification identifying confirmed albuminuria and potential eligibility for guideline-directed CKM therapies using existing electronic health record (EHR) data. Participants in the usual care arm will receive standard clinical care without notification.",[85,86],"Chronic Kidney Disease","Type 2 Diabetes",[88,89,90,91,92,93,94,95,96,97,98,99,100,101,86,85],"Cardio-Kidney-Metabolic Syndrome","Albuminuria","Urine Albumin-to-Creatinine Ratio","Guideline-Directed Medical Therapy","Electronic Health Record","Epic","Implementation Science","Pragmatic Trial","Renin-Angiotensin System Inhibitors","Sodium-Glucose Cotransporter-2 Inhibitors","Glucagon-Like Peptide-1 Receptor Agonists","Non-steroidal Mineralocorticoid Receptor Antagonists","Finerenone","CKM Care","NOT_YET_RECRUITING","2026-05-19",{"date":105,"type":106},"2026-05-26","ACTUAL",{"date":108,"type":79},"2026-08",{"date":110,"type":79},"2028-01",{"name":5,"class":6},2]